Inventor · disambiguated record
Alexandre Simonin
Also filed as: SIMONIN ALEXANDRE
6 granted patents·9 pending applications·1 citations·filing 2018–2024
67Inventor score
Technology areasC07K
Files withNumab Therapeutics AG15
Top patents by PatentIndex Score
15 records- 0173US11319371B2Anti-CD3 antibodiesNumab Therapeutics AG·Filed 2018·Granted May 3, 2022·1 cites·16 claims
- 0270US2025066482A1Antibodies targeting pdl1 and methods of use thereofNumab Therapeutics AG·Filed 2024·Application pending·0 cites
- 0362US2022403028A1Novel anti-cd3 antibodiesNumab Therapeutics AG·Filed 2022·Application pending·0 cites
- 0458US12077588B2Antibodies targeting PDL1 and methods of use thereofNumab Therapeutics AG·Filed 2018·Granted Sep 3, 2024·0 cites·28 claims
- 0556US2025282880A1Antibody variable domains that bind il-4rNumab Therapeutics AG·Filed 2021·Application pending·0 cites
- 0656US2024043547A1Antibody variable domains that bind il-31Numab Therapeutics AG·Filed 2021·Application pending·0 cites
- 0754US2023391882A1Combination treatmentNumab Therapeutics AG·Filed 2021·Application pending·0 cites
- 0853US12209133B2Antibodies targeting CD137 and methods of use thereofNumab Therapeutics AG·Filed 2019·Granted Jan 28, 2025·0 cites·25 claims
- 0951US12202911B2Multispecific antibody comprising CD137 binding domain and PDL1 binding domainNumab Therapeutics AG·Filed 2018·Granted Jan 21, 2025·0 cites·3 claims
- 1051US11578133B2Antibodies targeting CD137 and methods of use thereofNumab Therapeutics AG·Filed 2018·Granted Feb 14, 2023·0 cites·15 claims
- 1150US2025282879A1Multispecific antibodies having specificity for il-4r and il-31Numab Therapeutics AG·Filed 2021·Application pending·0 cites
- 1250US2024392003A1Multispecific antibodies having specificity for ror1 and cd3Numab Therapeutics AG·Filed 2022·Application pending·0 cites
- 1349US2023203162A1Multispecific antibodyNumab Therapeutics AG·Filed 2021·Application pending·0 cites
- 1446US2022411536A1Multispecific antibodyNumab Therapeutics AG·Filed 2020·Application pending·0 cites
- 1542US12098203B2Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSANumab Therapeutics AG·Filed 2018·Granted Sep 24, 2024·0 cites·25 claims
Join the waitlist — get patent alerts
Get an alert when Alexandre Simonin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →